NobleGen has disclosed several appointments to its board of directors and scientific advisory board.
Wolfgang Oster was appointed chairman of the board last September. He is the co-founder of Hemacon, Immunogenes, and Oncoceutics. He has held positions at PolyTechnos Venture-Partners and US BioScience. He holds an MD and PhD in internal medicine and hematology and oncology from Brown University and Germany's University of Freiburg.
Gavriel Meron was appointed to the board of directors in March. He is the chairman and CEO of MGD Management Services and Investments. Previously, he founded and served as CEO of Given Imaging, and was CEO of Applitec. He holds a BA in economics and statistics from Hebrew University of Jerusalem.
Chandra Venkatraman joined the board of directors in April. He has over 30 years experience in digital signal processing and communications, including over 10 patents in the area. Venkatraman was previously a senior scientist at Hewlett-Packard, the founder and chairman of Arula, and held positions at the Tata Institute. He holds an MS in electrical engineering from Concordia University in Montreal, and a BS in electrical engineering from Bangalore University.
George Church joined NobleGen's scientific advisory board in January. He is the director of the Harvard Center for Computational Genetics and a professor of genetics at Harvard Medical School.
Chad Nusbaum was appointed to the scientific advisory board in September. He is the head of sequencing operations at the Broad Institute. He holds a PhD in biology from MIT.
Zhiping Weng joined the scientific advisory board last June. He is a professor of molecular pharmacology and the director of the Center of Informatics and Integrative Biology at the University of Massachusetts Medical School. He holds a PhD in biomedical engineering from Boston University and a BS in electrical engineering from the University of Science and Technology of China.
Jorge Leon joined the scientific advisory board in February. He has held management positions at Quest Diagnostics and also founded Leomics Associates. He holds a PhD in cellular and molecular biology from New York University.